T/FIF, a New Plateau Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : T/FIF, a New Plateau

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (1031)	3/24/2002 5:08:53 PM
From: Biotech Jim	Read Replies (2) of 2243

I was under the impression that MK869, the NK1 antagonist that was being developed by MRK for emesis and depression, was in Ph 3. Perhaps at the time of the release, it was in Ph 2. This mechanism for depression may not have the sexual dysfunction side effects as the SSRIs, but from what I hear in the industry the efficacy is nowhere close to the other mechanisms being either marketed or those in the clinic currently. There is solid evidence that the compound and this mechanism displays efficacy for certain types of emesis, including chemotherapy-induced emesis. Also, the nanocrystal technology sounds like it could really be great. Most companies making small molecule drugs run into solubility issues ALL THE TIME. Rick, do you have any more info on this technology, or any pointers to it? TIA. BJ

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next